Elemental impurities in drug products may arise from several sources:

  • Present as residual catalysts that were added intentionally in synthesis.
  • Present as impurities through interactions with processing equipment or the container/closure systems.
  • They may be present in components of the drug product.

Elemental impurities do not provide any therapeutic benefit to the patient, but they may also adversely affect drug stability and shelf-life and they may lead to unwanted side effects for the end user. As such, the levels of elemental impurities must be monitored and controlled in drug substances, intermediates, excipients, and final drug products.

image
Scientech ensures compliance with stringent regulatory guidelines by swiftly and cost-effectively identifying and quantifying impurities in products.
Mid Banner

The United States, United States Pharmacopeia (USP) introduced new general chapters USP<232> and USP<233> to monitor and control elemental impurities in lieu of the 100-year-old colorimetric technique defined in the chapter USP<231>, also known as “Heavy Metals testing”. USP General Chapters specifications have followed the International Conference on Harmonization (ICH) limits established in the Guideline for Elemental Impurities Q3D. This process provides a platform for developing a risk-based control strategy to limit elemental impurities in the drug product.

image
image

ICHQ3D and USP<232> provide guidelines on Permitted Daily Exposures (PDEs) for elemental impurities. Permitted daily exposures (PDEs) for each element (Class 1, 2A, 2B, and 3) and the maximum allowable daily dosage of the drug product can be used for the evaluation of the permitted concentration of each element in that specific drug product.

The USP<233> chapter defines two analytical procedures for the evaluation of the levels of the elemental impurities. The chapter also describes criteria for acceptable alternative procedures (Limit Test procedures and Quantitative procedures). In the chapter, the use of modern instrumentation such as multi-element ICP-MS and ICP-OES is recommended.

Scientech has experts with years of knowledge and experience and state-of-the-art instrumentation (ICP-MS) to assist with all your USP<232>/ USP<233> ICHQ3D Elemental Impurities testing (Trace Metals Analysis) requirements in a cGMP, FDA-regulated setting.

image
Do you Need help in
Contact us

cGMP

cGMP compliant

FDA

FDA registered

DEA

DEA licensed

SOPs

Documentation